The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Patients with acquired thrombotic thrombocytopenic purpura (aTTP) showed significant benefits in critical outcomes when treated with caplacizumab as well as the standard regimen. Using caplacizumab to ...

Investigators said they were able to confirm diagnoses of systemic lupus erythematosus (SLE) and thrombotic thrombocytopenic purpura (TTP) because they took a multidisciplinary approach. Thrombotic ...

The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia (fitusiran) for haemophilia and Cablivi (caplacizumab) ...

* Decision follows it's review of initial results from study demonstrating a non-favourable risk benefit profile * This decision to discontinue study has no impact on Hansa Medical's ongoing studies ...

For the past two years, the research lab of X. Long Zheng, M.D., Ph.D., Division Director, Laboratory Medicine, UAB Department of Pathology, has hosted an annual Thrombotic Thrombocytopenic Purpura ...